[1] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology, 2019, 156(8):2230-2241,e11. [2] Zhou Y, Yang L, Liao Z, et al. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol, 2013, 25(7):825-829. [3] Zhang C, Wu Y, Yuan S, et al. Characteristics of drug-induced liver injury in Northeast China: Disease spectrum and drug types. Dig Dis Sci, 2020, 65(11):3360-3368. [4] Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol, 2016, 65(3):532-542. [5] Weersink RA, Alvarez-Alvarez I,Medina-Cáliz I, et al. Clinical characteristics and outcome of drug-induced liver injury in the older patients: From the young-old to the oldest-old. Clin Pharmacol Ther, 2021, 109(4):1147-1158. [6] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志, 2015, 23(11): 810-820. [7] 肖亮. 肝脏穿刺活检湘雅专家共识. 中国普通外科杂志, 2021, 30(1):1-8. [8] Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut, 2020, 69(8):1382-1403. [9] Xiong YT, Wang JF, Niu XX, et al. Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury. Front Pharmacol, 2023, 14:1071709. [10] Danjuma MI, Almasri H, Alshokri S, et al. Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score. BMC Geriatr, 2020, 20(1):346. [11] Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol, 2015, 63(2):503-514. [12] Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology, 2013, 144(7):1419,e20. [13] Koch L. Therapy: Propylthiouracil use associated with severe hepatotoxicity in children. Nat Rev Endocrinol, 2010, 6(8):416. [14] Allard J, Le Guillou D, Begriche K, et al. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Adv Pharmacol, 2019, 85:75-107. [15] Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis, 2014, 18(1):165-178. [16] 刘如玉, 路遥, 申戈, 等. HBeAg 阴性初治慢乙肝患者恩替卡韦4年抗病毒治疗FIB-4评分动态变化研究. 中华实验和临床病毒学杂志, 2020, 34(1): 51-56. [17] 李晓芸,钟巍,茅益民. 他汀类药物相关药物性肝损伤. 中华肝脏病杂志, 2023, 31(6):659-663. [18] 林云霞,何晓彬. 药物性肝损伤的临床特点及危险因素分析. 临床肝胆病杂志, 2018, 34(6):1237-1241. [19] 王焱, 周静, 韩军. 自身免疫性肝炎和药物性肝损伤患者临床病理特征分析. 实用肝脏病杂志, 2023, 26(2):218-221. [20] Puri M. Automated machine learning diagnosticsupport system as a computational biomarker for detecting drug-induced liver injury patterns in whole slide liver pathology images. Assay Drug Dev Technol, 2020, 18(1):1-10. |